Table 1.

Examples of agents that target TAMs in clinical trials.

Treatment strategy	Agent name	Target	Drug type	Phase	Clinical trial number
Inhibit TAMs recruitment	Carlumab	CCL2	CCL2 antibody	II	NCT00992186
				I	NCT00537368
				Ib	NCT01204996
	MLN1202	CCR2	CCR2 antagonist	II	NCT01015560
	PF-04136309	CCR2	CCR2 antagonist	Ib	NCT01413022
	AZD5069	CCR2	CCR2 antagonist	I/II	NCT03177187
	CCX872-B	CCR2	CCR2 antagonist	Ib	NCT02345408
	Ulocuplumab	CXCR4	CXCR4 antibody	I	NCT01120457
	LY2510924	CXCR4	CXCR4 antibody	I	NCT02737072
	PTX-9908	CXCR4	CXCR4 antagonist	I/II	NCT03812874
	Motixafortide	CXCR4	CXCR4 antagonist	I/IIa	NCT01010880
				IIb	NCT02907099
Depletion of TAMs	MCS110	CSF-1	CSF-1 antibody	Ib/II	NCT02807844
				II	NCT03785496
	PLX3397	CSF-1R	CSF-1R inhibitor	I	NCT02777710
				Ib/II	NCT01596751
				III	NCT02371369
	DCC-3014	CSF-1R	CSF-1R inhibitor	I/II	NCT03069469
	BLZ945	CSF-1R	CSF-1R inhibitor	I/II	NCT02829723
	FPA008	CSF-1R	CSF-1R antibody	I	NCT03158272
				II	NCT02471716
	Bisphosphonates	NA	Small molecule	III	NCT00127205
				II	NCT00091832
	Trabectedin	Caspase 8	Small molecule	I	NCT03985722
				II	NCT02194231
Reprogramming TAMs	Hu5F9-G4	CD47	CD47 antibody	I	NCT02953782
	CC-95251	SIRPα	SIRP antibody	I	NCT03783403
	RO7009789	CD40	CD40 agonist	I	NCT02665416
	SEA-CD40	CD40	CD40 agonist	I	NCT02376699
	CP-870893	CD40	CD40 agonist	I	NCT01103635
	GSK1795091	TLR4	TLR agonist	I	NCT03447314
	IMO-2125	TLR7/8	TLR agonist	I	NCT03052205
				I/II	NCT02644967
				III	NCT03445533
	CMP-001	TLR9	TLR agonist	II	NCT03618641
	IPI-549	PI3Kγ	PI3Kγ inhibitor	Ib	NCT02637531
	YY-20394	PI3Kγ	PI3Kγ inhibitor	I	NCT03757000
	Chidamide	HDAC	HDAC inhibitor	II	NCT04512534